Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12537733 | 0.85 | NTRK1 (0.53) | NTRK1NTRK2PBRM1CSNK2A2CSNK2A1 | |
| SCHEMBL13869070 | 0.83 | NTRK1 (0.48) | NTRK1NTRK2CSNK2A2CSNK2A1TNK2 | |
| SCHEMBL13869078 | 0.82 | NTRK1 (0.51) | NTRK1NTRK2PBRM1CSNK2A2CSNK2A1 | |
| SCHEMBL12537729 | 0.82 | NTRK1 (0.48) | NTRK1NTRK2PBRM1CSNK2A2CSNK2A1 | |
| SCHEMBL12537587 | 0.82 | NTRK1 (0.73) | NTRK1NTRK2PBRM1CSNK2A2CSNK2A1 | |
| SCHEMBL12537482 | 0.80 | NTRK2 (0.53) | NTRK1NTRK2PBRM1CSNK2A2CSNK2A1 | |
| SCHEMBL1925784 | 0.78 | NTRK2 (0.78) | NTRK1NTRK2NPC1LMNA | |
| SCHEMBL19279707 | 0.77 | CSNK2A2 (0.39) | NTRK1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL14651915 | 0.77 | NTRK1 (0.38) | NTRK1NTRK2CSNK2A2CSNK2A1TNK2 | |
| SCHEMBL13869055 | 0.77 | MAPK14 (0.47) | NTRK1NTRK2PBRM1CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| WO-2007061882-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK1 3/4885NTRK2 1/4885PBRM1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.